How long does it usually take for veentuzumab/besifu to be effective?

Enfortumab/Enfortumab, as an antibody-drug conjugate, provides a new treatment option for patients with advanced urothelial cancer (bladder cancer). One of the biggest questions many patients have when starting to use this drug is: How long will it take to see results? In fact, the answer to this question depends on the mechanism of action of the drug itself, individual patient differences, and the rate of disease progression.

What is special about venetuzumab is that it combines an antibody with a cytotoxin and can specifically recognize the target protein on the surface of cancer cells. After the drug enters the tumor cells, it releases toxins, destroys the cytoskeleton, and ultimately leads to cell death. Because this mechanism of action is direct and rapid, some patients can observe tumor shrinkage or symptom improvement in a relatively short period of time. In clinical trials, some patients experienced significant responses in the first few courses of treatment, including tumor imaging reduction and pain relief.

However, not all patients experience results in the same time. "Response" in cancer treatment usually refers to tumor shrinkage or disease stabilization visible on imaging, and this process is affected by many factors, including tumor load size, metastasis site, immune status of the body, and resistance to previous treatments. Therefore, some patients may gradually show efficacy after 2 to 3 courses of treatment, while other patients may even need longer maintenance treatment to observe improvement in their condition.

For doctors, judging whether a drug is effective does not solely rely on imaging results, but also requires comprehensive consideration of the patient's clinical manifestations and quality of life. In terms of treatment course management, veentuzumab is usually continued until disease progression or patients experience intolerable toxicity. If the patient does not show significant effects in the early stage, but the overall condition is stable and does not deteriorate significantly, doctors will usually recommend continuing treatment to observe the subsequent cumulative effects.

Reference: https://www.padcev.com/